Waypoint points way forward for Stallergenes

London-headquartered allergy specialist Stallergenes Greer (Euronext: STAGR) is set to go private in a 730.1 million euros ($832 million) takeover by its majority shareholder, Waypoint.

Being free from shareholders considerations will allow Stallergenes Greer's management team to focus on the successful implementation of its business objectives without the distraction of listing obligations, the drugmaker said in a statement.

“Enabling the management team to focus on the execution of the business objectives without this distraction is particularly important as Stallergenes Greer continues to recover from the difficult operational challenges of recent years,” the statement adds.